Short answer
Corvus Pharmaceuticals, Inc. (CRVS) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$20M
- −100.3% YoY · −13.3% QoQ
- EPS (diluted)
- −$0.22
- −83.3% YoY · −10.0% QoQ
Source: XBRL data from the Corvus Pharmaceuticals, Inc. (CRVS) Q3 2026 10-Q on SEC EDGAR. USD.
Corvus Pharmaceuticals, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales or collaboration revenue
- Net loss $20.3M vs $10.2M YoY, operating margin not applicable due to zero revenue
- Soquelitinib R&D costs $12.5M vs $5.6M, largest program and $6.9M YoY increase
- Cash used in operations $38.0M, cash resources $202.9M after $189.4M equity offering
- Funding expected through Q2 2028, additional capital required amid ongoing clinical-development losses
Risk Factors
- No material changes identified versus the 10-K, with risks largely carried forward
- Liquidity risk: $202.9 million in cash, equivalents and marketable securities expected to fund operations into Q2 2028
- Financial performance risk: $52.0 million net loss and $464.3 million accumulated deficit for nine months ended September 30, 2026
- Regulatory risk: FDA may reject foreign clinical-trial data, potentially requiring additional costly trials
- Operational risk: Third-party manufacturers remain subject to cGMP failures that could suspend trials or delay approvals
- Competitive risk: Larger, better-funded oncology companies may develop more effective therapies faster
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Corvus Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.